Full-Time

Head of Ethics & Compliance Operations

Oncology

Posted on 4/1/2025

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm developing treatments and vaccines

Compensation Overview

$174.5k - $274.2k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Boston, MA, USA

This position is currently classified as 'hybrid' in accordance with Takeda's Hybrid and Remote Work policy.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Data Analysis
Requirements
  • 10 years of Ethics & Compliance (or comparable) experience, with at least 5 years as part of healthcare or pharmaceutical industry
  • Familiarity with US Federal & State transparency reporting requirements
  • Demonstrated knowledge of key laws, regulations and industry best practice standards
  • Experience in aligning potential, present and future compliance risks related to the business, including risk identification, controls & risk mitigation of potential non-compliance
  • Demonstrated operational efficiency through utilization of technology
  • Acts as role model for Takeda’s values, ethics and values-based decision making
  • High interpersonal and communication skills including ability to challenge and provide guidance to business
  • Demonstrates ability to deliver results through commitments made and projects managed
  • Ability to liaise and work effectively with the OBU E&C Business Partners Team (i.e., ensuring relevant analytics and monitoring output is incorporated into Advisory's ongoing risk mitigation planning) as well as with other E&C Operations groups
  • Ability to work with and comprehend significant detail and complexity
  • Demonstrable ability to deliver results
  • Personal and professional maturity, able to motivate and inspire
Responsibilities
  • Incumbent plays a fundamental role in strengthening the OBU E&C Program by coordinating the deployment of Global initiatives in alignment with OBU E&C Business Partners and by providing input to different stakeholders (Global Ethics & Compliance, OBU functions, etc.) to continuously enhance the Program, global platforms and systems where relevant
  • Finds synergies and alignment with other BU E&C teams when possible and relevant
  • Generates relevant reports providing strategic insight to relevant functions
  • Serves as the OBU Risk, Ethics and Compliance Committee (RECC) secretary
  • Responsible for operational elements of the OBU E&C Program, in coordination with OBU E&C Partners team
  • Represents OBU E&C in relevant Global E&C projects and initiatives
  • Support OBU audit governance initiatives
  • Member of OBU E&C Leadership team
  • Coordinate and execute monitoring activities in partnership with E&C Partners and other supporting functions. Collaborate with local E&C officers in the EUCAN OBU countries and Japan on OBU monitoring, ensuring identification of trends relevant to the OBU business and E&C program
  • Evolve the OBU monitoring program and collaborate on the global monitoring program
  • Coordinate with OBU E&C Partners Team and OBU business areas on remediation plans
  • Leads OBU compliance risk assessments
  • Oversees Tier 3 OBU investigations assignments, ensuring follow through to completion
  • Support the US transparency team in OBU data validation and other necessary tasks to ensure accurate and complete reporting of Federal and State reportable transfers of value
  • Develop OBU-specific analytics and reports that proactively identify non-compliant activities
  • Drives the development and implementation of required compliance policies, SOPs & guidelines in OBU

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to provide life-changing therapies while ensuring that patient needs are prioritized and environmental risks are managed.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene could enhance its immunology and neurology offerings.
  • The SEA AtM Summit highlights Takeda's commitment to expanding access to medicines in Asia.
  • Positive Phase III trial results for a cancer drug strengthen Takeda's oncology portfolio.

What critics are saying

  • Antitrust litigation in the US could impact Takeda's market position and reputation.
  • The $770 million deal with BridGene poses financial risks if outcomes aren't met.
  • Geopolitical risks could disrupt Takeda's global operations and supply chain.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and innovations.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Nyasa Times
Feb 6th, 2025
Forgotten Children: Mzimba's Tukuyu CBCC Struggles to Provide Basic Education

VillageReach, in partnership with Takeda Pharmaceutical Company Limited, has launched a new initiative aimed at strengthening health systems and improving...